Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Welcome to our Tumor Mutation Burden (TMB) Analysis Services page, where we specialize in providing comprehensive TMB analysis to help researchers and clinicians advance their understanding of cancer. Our goal is to empower you with the necessary tools and insights to explore the complexity of tumor genetics and its implications in personalized medicine. By utilizing advanced technology and methodologies, we aim to unravel the genetic landscape of tumors, assisting in the development of targeted therapies and innovative treatment strategies.
The term "tumor mutation burden" describes the overall number of mutations found in the genome of a malignant tumor. It is an emerging biomarker that has garnered significant attention in oncology, particularly regarding its role in immunotherapy. Higher TMB has been associated with increased neoantigen presentation, which can enhance the immune system's ability to recognize and attack cancer cells. Consequently, TMB serves as a crucial indicator in predicting patient responses to immune checkpoint inhibitors and other personalized therapeutic approaches. Knowing TMB is essential for creating individualized treatment programs since it sheds light on the unique molecular characteristics of each tumor.
Fig.1 Tumor mutational burden in tumor.1
To satisfy our clients' various needs, we provide two specialist TMB analysis services:
Next-Generation Sequencing based Tumor Mutation Burden (TMB) Analysis Service
Our Next-Generation Sequencing-based Tumor Mutation Burden (TMB) Analysis Service provides precise, high-throughput analysis of the total number of somatic mutations within a tumor genome, enabling accurate assessment of TMB to support immunotherapy strategies by identifying those who may benefit from immune checkpoint inhibitors and other targeted cancer treatments.
Please click on the keywords above to learn more information!
High TMB is associated with a higher number of neoantigens, which may improve the immune system's ability to recognize and attack tumors, making it useful for predicting responses to immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors).
TMB analysis helps track tumor evolution over time, detect treatment resistance, and inform therapy adjustments.
A non-invasive method of tracking tumor recurrence, detecting minimal residual disease, and monitoring therapy response is liquid biopsy, which can assess TMB from blood or other biofluids.
Selecting our TMB Analysis Services offers the following significant benefits:
Cutting-Edge Technology: To guarantee accurate and dependable results and provide our clients confidence in their data, we employ the most recent developments in sequencing technologies.
Expert Team: Our team consists of experienced scientists and bioinformaticians with a deep understanding of oncology and genetic analysis, dedicated to providing personalized support throughout the research process.
Comprehensive Reports: We deliver detailed reports that include insights and interpretations of TMB data, facilitating a better understanding of its implications for treatment options.
Tailored Solutions: We recognize that each research endeavor is distinct. Thus, whether for therapeutic purposes or scholarly research, we provide customized solutions to satisfy particular needs.
We invite you to explore our Tumor Mutation Burden Analysis Services to advance your research endeavors. Please get in touch with our team right now if you have any questions or to talk about how we can help. We are here to provide you with the expertise and support necessary to navigate the complexities of tumor genetics and to help you achieve your research goals. Reach out to us via email or phone, and let's embark on a journey to uncover the intricacies of cancer together.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
